Discover how Chroma is expanding our impact.

Brisbane, California, and Boston, Massachusetts, JULY 20, 2023 – Sangamo Therapeutics, Inc. (Nasdaq: SGMO), a clinical-stage genomic medicine company and Chroma Medicine, Inc. (Chroma) a genomic medicine company pioneering single-dose epigenetic editing therapeutics, today announced they have entered into a research evaluation, option and license agreement to develop epigenetic medicines leveraging zinc finger proteins (ZFPs) for sequence-specific DNA recognition. Over the course of two decades, Sangamo has built and validated the world’s largest library of ZFPs, deploying them to address numerous therapeutically relevant targets.  Advancing the transformative potential of epigenetic editing, Chroma is expanding the versatility of its platform by…

Boston, MA, May 19, 2023 – Chroma Medicine, Inc., (Chroma) a genomic medicine company pioneering single-dose epigenetic editing therapeutics, today presented data demonstrating the advantages of epigenetic editing for multiplex gene regulation at the American Society of Gene & Cell Therapy (ASGCT) 26th Annual Meeting in Los Angeles. Chroma’s epigenetic editing platform harnesses the cell’s endogenous mechanism for regulating gene expression to durably modulate transcription without cutting or nicking the DNA, offering a potentially safer approach for multiplex editing. This avoids challenges associated with gene editing methods that rely upon DNA breaks to alter gene expression, which have the potential…

Boston, MA, May 18, 2023 – Chroma Medicine, Inc., (Chroma) a genomic medicine company pioneering single-dose epigenetic editing therapeutics, today announced in vivo data that demonstrate 99% silencing of two distinct targets and compelling proof-of-concept for its epigenetic editing platform. The data presented at the American Society of Gene & Cell Therapy (ASGCT) 26th Annual Meeting showcase the rapid advancement of the company’s programs and platform. The work describes the development of Chroma’s epigenetic editor targeting PCSK9, a well-characterized genetic target for addressing hyperlipidemia. The company’s epigenetic editor showed highly effective, durable, and specific silencing of PCSK9 in a transgenic…